Stock analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report released on Tuesday. The firm set a "sell" rating on the biotechnology company's stock.
Bellerophon Therapeutics Stock Performance
Shares of BLPH opened at $1.14 on Tuesday. The stock's 50-day simple moving average is $1.30 and its 200 day simple moving average is $1.39. Bellerophon Therapeutics has a 52-week low of $0.67 and a 52-week high of $4.49. The stock has a market capitalization of $10.88 million, a price-to-earnings ratio of -0.58 and a beta of -0.02.
Get Bellerophon Therapeutics alerts:Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last released its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.18. On average, research analysts forecast that Bellerophon Therapeutics will post -2.21 earnings per share for the current fiscal year.
Institutional Trading of Bellerophon Therapeutics
A hedge fund recently raised its stake in Bellerophon Therapeutics stock. Renaissance Technologies LLC raised its holdings in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) by 13.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 209,399 shares of the biotechnology company's stock after acquiring an additional 24,100 shares during the period. Renaissance Technologies LLC owned approximately 2.19% of Bellerophon Therapeutics worth $258,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.92% of the company's stock.About Bellerophon Therapeutics
(Get Rating)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Read More
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- 3 Stocks Growing Their Businesses for 2023
- China-Based EV Maker BYD Set For Big European, Japanese Expansion
- Is Illumina Still the Gamechanger in Genomics Sequencing?
- Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut
- The Institutions Bought CarMax In Q3, Now It's Cheaper
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.